Novartis Ag

Other

Novartis Pharma Gmbh

Yves Auberson

Hans Allgeier

Thomas Josef Troxler

Silvio Ofner

Siem Jacob Veenstra

Mark G Bock

Piotr Henryk Karpinski

Dario Braga

Marina Tintelnot-Blomley

Stephanie Kay Dodd

Manuel Koller

Claudia Betschart

Joachim Nozulak

Henri Mattes

Wolfgang Froestl

David Orain

Xiaoyang Wang

Stefano Luca Giaffreda

Johanne Renaud

Tie-Lin Wang

Oliver Simic

Michel Biollaz

Darren Mark Le Grand

Robert Mah

Stefanie Flohr

Walter Schilling

Rainer Machauer

Marc Gerspacher

Simon Mensah Ametamey

Nicholas David Cosford

Roland Heckendorn

Joerg Kallen

Fabrizio Gasparini

Samuel Hintermann

Darren Mark Legrand

David Carcache

Ralf Glatthar

Xuechun Zhang

Jörg Kallen

Philipp Floersheim

Christel Guibourdenche

Marco Curzi

Berndt Oberhauser

Pierre Acklin

Emmanuelle Briard

Haiyang Jiang

Andreas Von Sprecher

Terance William Hart

Eric Vangrevelinghe

Siem J Veenstra

Silvio Roggo

Edwin Carl Johnson

Kurt Laumen

Robert Moretti

Rainer Kuhn

Kaspar Zimmermann

G&ouml;n&uuml;l Veli&ccedil;elebi

Mark Andrew Varney

Tielin Wang

Rhys Salter

Hayang Jiang

Kaspar Zimmerman

Lea Kessler

Mark Gary Bock

Preparation of novel 2-benzyl-5-methyl-2H-tetrazole derivatives of the formula (I) for use as PET imaging agents. The present invention relates to novel compounds of formula (I) their preparation and use as PET imaging agents for imaging techniques and diagnostics in the field of diseases and disorders mediated by or related to the enzyme autotaxin. 

Pet imaging agents

PET Imaging agents

The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Carbamate/urea derivatives

The present invention relates to novel pyridylacetylene derivatives of formula I their preparation, their use as radio-traces/markers and compositions containing them.

Pyridylacetylenes for use as radiotracers and imaging agents

The invention provides compounds of formula I wherein n, A, R, R', R&#x2033;, R, X and Y are as defined in the description, and their preparation. The compounds of formula I are useful as pharmaceuticals.

Acetylene derivatives having MGluR 5 antagonistic activity

The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein Rand Rare as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy

N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide

The present invention relates to novel 2-(6-oxo-1,7-diaza-spiro[4.4]non-7-yl)-propionamides of the formula wherein R, R, R, R, R, R, m and p are as defined in the specification, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions containing them.

Certain substituted spirocyclic lactams and use thereof as pharmaceuticals

Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands

The present invention relates to novel benzo[1,2,5]oxadiazoles and benzo[1,2,5]thiadiazoles of formula (I) wherein X is O or S, Ris 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-F-ethylamino)-thiazol-2-yl or a group of formula (a) wherein Y is CH or N, Ris NHCH, NHCH, N(CH)CH, N(CH), N(CH), NH(CH)F, NH(CH)F, N(CH)(CH)F, N(CH)&#x2014;(CH)F, O&#x2014;(CH)F, O&#x2014;(CH)F, CONH(CH)nF or CONH(CH)F (n being in each case 2 to 4) and Ris hydroxy, (C1-4)alkoxy, hydrogen or nitro, in free base or acid addition salt form; their preparation, their use as markers in diagnosis and compositions containing them.

Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers

The present invention pertains to novel dibenzo[b,f]oxepine-10-carboxamides compound to a process for the preparation of such compounds of formula I, their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula I.

Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof

The present invention relates to novel macrocyclic compounds of the formula wherein R, R, R, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Macrocyclic lactams and pharmaceutical use thereof

The invention provides compounds of formula (I), wherein R, R, R, Rand Rare as defined in the description, and their preparation. The compounds of formula I are useful as biomarkers. 

Coumarines useful as biomarkers

Growing community of inventors

Allschwil, Switzerland

Yves Auberson